Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $42.05
  • 50 Day Moving Average: $38.33
  • 200 Day Moving Average: $39.60
  • 52-Week Range: $535,105,000.00 - $33.60
  • Trailing P/E Ratio: 84.27
  • Foreward P/E Ratio: 7.89
  • P/E Growth: 1.00
  • Market Cap: $22.50B
  • Outstanding Shares: 535,105,000
  • Beta: 1.14
  • Net Margins: 2.50%
  • Return on Equity: 22.04%
  • Return on Assets: 8.43%
  • Debt-to-Equity Ratio: 1.10%
  • Current Ratio: 0.83%
  • Quick Ratio: 0.55%
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 8 Hold Ratings, 9 Buy Ratings, 2 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $52.00 (23.66% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetDetails
1/5/2017GuggenheimReiterated RatingNeutralView Rating Details
1/5/2017Citigroup Inc.DowngradeBuy -> Neutral$59.00 -> $44.00View Rating Details
1/3/2017BTIG ResearchReiterated RatingBuy$55.00View Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveView Rating Details
12/7/2016MizuhoReiterated RatingBuy$49.00 -> $47.00View Rating Details
11/10/2016RBC Capital MarketsReiterated RatingSector Perform$48.00 -> $44.00View Rating Details
11/10/2016Barclays PLCReiterated RatingHold$44.00View Rating Details
10/10/2016J P Morgan Chase & CoSet Price TargetBuy$52.00View Rating Details
10/10/2016Raymond James Financial, Inc.UpgradeMarket Perform -> Strong-Buy$57.00View Rating Details
10/1/2016Leerink SwannSet Price TargetBuy$55.00 -> $45.00View Rating Details
10/1/2016Wells Fargo & CompanySet Price TargetHold$44.00View Rating Details
9/22/2016ArgusSet Price TargetBuy$55.00View Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00View Rating Details
9/23/2016Deutsche Bank AGSet Price TargetBuy$60.00 -> $58.00View Rating Details
9/6/2016Royal Bank Of CanadaLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00View Rating Details
8/25/2016Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy$60.00View Rating Details
8/24/2016Bank of America CorpReiterated RatingBuy$70.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015Susquehanna Bancshares IncLower Price TargetPositive$85.00 -> $68.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q3 2016$1.45$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.74 EPS
Next Year EPS Consensus Estimate: $5.33 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 60.89%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mylan (NASDAQ:MYL)
News IconCheap cialis - Price for 5 mg Cialis - Cialis 30 Day Sample (NASDAQ:MYL) - February 19 at 5:46 PM
News IconAarp rx - Rx drugs - Walmart pharmacy (NASDAQ:MYL) - February 19 at 5:46 PM
News IconJoe Nocera: The twisted world of Big Pharma keeps drug prices outrageously high (NASDAQ:MYL) - February 19 at 5:46 PM
News IconDrugmakers play games to keep prices high (NASDAQ:MYL) - February 19 at 5:46 PM
News IconUSFDA accepts Mylan's BLA for proposed biosimilar Pegfilgrastim (NASDAQ:MYL) - February 19 at 5:46 PM
News IconMylan NV (NASDAQ:MYL) Met Earnings 1 times (NASDAQ:MYL) - February 18 at 5:56 PM
News IconRat found in midday meal (NASDAQ:MYL) - February 18 at 11:33 AM logo10-K: ABBOTT LABORATORIES (NASDAQ:MYL) - February 17 at 4:57 PM
News IconWhat are Analysts report about: Mylan NV (NASDAQ:MYL) (NASDAQ:MYL) - February 17 at 4:57 PM logoMylan's Proposed Biosimailar for Cancer Under Review in U.S. (NASDAQ:MYL) - February 17 at 4:57 PM
News IconFDA Accepts Mylan aBLA or Pegfilgrastim Biosimilar (NASDAQ:MYL) - February 16 at 6:18 PM logoMylan (MYL) Says FDA Accepts BLA for Biocon's Proposed Biosimilar Pegfilgrastim for Review (NASDAQ:MYL) - February 16 at 6:18 PM logoTepper's Appaloosa triples stake in Allergan (NASDAQ:MYL) - February 16 at 6:18 PM logoU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review (NASDAQ:MYL) - February 16 at 6:18 PM logo8:10 am Mylan N.V. announces that the FDA has accpeted its BLA for MYL-1401H for filing through the 351(k) pathway; FDA goal date set under the Biosimilar User Fee Act (BsUFA) is Oct. 9, 2017 (NASDAQ:MYL) - February 16 at 6:18 PM logoTrump's pick to lead health agency calls EpiPen issue 'disturbing' (NASDAQ:MYL) - February 16 at 6:18 PM logoBRIEF-Paulson & Co cuts share stake in Fedex, Mylan (NASDAQ:MYL) - February 14 at 9:11 PM logoMylan Shares Unchanged as Kaleo Releases EpiPen Competitor (NASDAQ:MYL) - February 14 at 9:11 PM logoMylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines (NASDAQ:MYL) - February 14 at 9:11 PM logoMarathon pauses Duchenne drug launch amid price outcry (NASDAQ:MYL) - February 13 at 7:52 PM logoCompany announces pause for drug after price criticism (NASDAQ:MYL) - February 13 at 7:52 PM
News IconLarge Outflow of Money Witnessed in Mylan NV - Highland Mirror (NASDAQ:MYL) - February 13 at 10:03 AM logoGames Drugmakers Play (NASDAQ:MYL) - February 13 at 10:03 AM
News IconWhat are Analyst's Indicators for Mylan NV (MYL), Nucor Corporation (NUE) (NASDAQ:MYL) - February 10 at 7:40 PM
News IconWells Fargo & Company Reaffirms Market Perform Rating for Gilead Sciences, Inc. (GILD) (NASDAQ:MYL) - February 9 at 7:47 PM
News IconMylan NV (MYL), Chevron Corporation (CVX) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:MYL) - February 8 at 7:36 PM logoGlaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns (NASDAQ:MYL) - February 8 at 7:36 PM
News IconConcerns Diverting Active Stocks Direction: Quantum Corporation (NYSE:QTM), Mylan NV (NASDAQ:MYL) - Street Wise Report (press release) (blog) (NASDAQ:MYL) - February 8 at 1:19 AM logoHow These Generic Drugs Stocks are Faring? -- Mylan, Allergan, Horizon Pharma, and Catalent (NASDAQ:MYL) - February 7 at 8:18 PM
News IconMylan NV (MYL) Consensus EPS Forecasts (NASDAQ:MYL) - February 7 at 8:18 PM logoStocks Under Consideration: Mylan NV (MYL), Host Hotels & Resorts, Inc. (HST), Target Corporation (TGT) - iStreetWire (NASDAQ:MYL) - February 7 at 3:16 PM
News IconDrilling Down Into the Charts for Mylan NV (MYL) - The USA Commerce (NASDAQ:MYL) - February 7 at 3:16 PM
News IconWhy to Keeping Eye on Mylan NV (MYL), Host Hotels & Resorts, Inc. (HST)? - StockNewsJournal (NASDAQ:MYL) - February 7 at 3:16 PM logoFaber Report: Pharma fumbles (NASDAQ:MYL) - February 7 at 3:16 PM logoPerrigo adds three directors in deal with activist Starboard (NASDAQ:MYL) - February 7 at 3:16 PM logoThere Is Nothing Generic About the Basing Action on Mylan (NASDAQ:MYL) - February 7 at 3:16 PM logoWhy This Stock Could Triple In A Couple Of Years (NASDAQ:MYL) - February 7 at 3:16 PM logoDespite Settling Decade-Long Suit, Mylan Shares Fall (NASDAQ:MYL) - February 7 at 3:16 PM
News IconA Look Ahead For 2 Stocks: Mylan NV (NASDAQ:MYL), Power Solutions International, Inc. (NASDAQ:PSIX) - Post Analyst (NASDAQ:MYL) - February 7 at 9:11 AM logoMylan agreed to pay $96.5 million in Provigil antitrust class action - Reuters (NASDAQ:MYL) - February 7 at 9:11 AM
News IconGlobal Branded Generics Market projected to reach US$ 413.8 Bn Market value By 2026-End (NASDAQ:MYL) - February 6 at 11:50 PM logoMylan agreed to pay $96.5 mln in Provigil antitrust class action (NASDAQ:MYL) - February 6 at 6:49 PM logoUnusual activity: Bullish bet on MSFT & MYL (NASDAQ:MYL) - February 6 at 6:49 PM logoMylan to Pay $96.5 Million to Settle Generic Provigil Claims (NASDAQ:MYL) - February 6 at 6:49 PM
News IconRegenerative Artificial Skin Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024 (NASDAQ:MYL) - February 4 at 11:45 PM logoMylan to Host Investor Day on March 1, 2017 in New York City (NASDAQ:MYL) - February 4 at 12:30 AM
News IconEarnings Forecast Research on Mylan N.V. (MYL) - Highland Mirror (NASDAQ:MYL) - February 3 at 7:28 PM
News IconToday Analysts Focus on Halliburton Company (HAL), Mylan NV (MYL) - StockNewsJournal (NASDAQ:MYL) - February 3 at 7:28 PM
News IconMylan NV (MYL) : How Do the Technicals Stack Up? - The USA Commerce (NASDAQ:MYL) - February 3 at 7:28 PM logoMylan NV is trading above its 50 day moving average : MYL-US : February 3, 2017 (NASDAQ:MYL) - February 3 at 5:38 AM


What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Where is Mylan's stock going? Where will Mylan's stock price be in 2017?

19 brokers have issued twelve-month target prices for Mylan's stock. Their forecasts range from $44.00 to $70.00. On average, they anticipate Mylan's share price to reach $52.00 in the next year.

When will Mylan announce their earnings?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Mylan stock?

Mylan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.73%), FIL Ltd (0.81%), Menora Mivtachim Holdings LTD. (0.55%), Dimensional Fund Advisors LP (0.43%), Renaissance Technologies LLC (0.28%) and FMR LLC (0.26%). Company insiders that own Mylan stock include Heather M Bresch, John D Sheehan, Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich, Robert J Coury and Wendy Cameron.

Who sold Mylan stock? Who is selling Mylan stock?

Mylan's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, Allianz Asset Management AG, AQR Capital Management LLC, RidgeWorth Capital Management LLC, TCW Group Inc., Mayo Investment Advisers LLC and American National Insurance Co. TX. Company insiders that have sold Mylan stock in the last year include Heather M Bresch and Robert J Coury.

Who bought Mylan stock? Who is buying Mylan stock?

Mylan's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc., Yost Capital Management L.L.C., Hodges Capital Management Inc., Baird Financial Group Inc. and Credit Agricole S A. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon, Mark W Parrish, Melina E Higgins, Robert J Cindrich and Wendy Cameron.

How do I buy Mylan stock?

Shares of Mylan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mylan stock cost?

One share of Mylan stock can currently be purchased for approximately $42.05.

Mylan (NASDAQ:MYL) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Earnings History Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Dividend History Chart

Dividend Payments by Quarter for Mylan (NASDAQ:MYL)

Last Updated on 2/19/2017 by Staff